Overview

TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors

Status:
Terminated

Trial end date:
2020-11-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find out if removing a specific type of white blood cell (called alpha beta T-cell) that help make up the transplant donor's stem cells can improve results of blood stem cell transplant for the participant's disease.

Phase:

Phase 2

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Treatments:

Antilymphocyte Serum
Clofarabine
Fludarabine
Fludarabine phosphate
Melphalan
Thiotepa
Thymoglobulin
Vidarabine